Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Krishnan

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
Blood|February 23, 2024
A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expressionMariam Murtadha, Miso Park, Yinghui Zhu, et al.
JCO Precision Oncology|January 18, 2024
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of MalignanciesMark M Stevens, Robert J Kimmerling, Selim Olcum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2016
Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case ForumPere Barba, Linda J Burns, Mark R Litzow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
Cancer Medicine|October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple MyelomaNiels W C J van de Donk, Ajai Chari, Thomas Martin, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
Blood|February 23, 2024
A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expressionMariam Murtadha, Miso Park, Yinghui Zhu, et al.
JCO Precision Oncology|January 18, 2024
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of MalignanciesMark M Stevens, Robert J Kimmerling, Selim Olcum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall SurvivalMarcelo C Pasquini, Paul K Wallace, Brent Logan, et al.
The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2016
Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case ForumPere Barba, Linda J Burns, Mark R Litzow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
Cancer Medicine|October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple MyelomaNiels W C J van de Donk, Ajai Chari, Thomas Martin, et al.
Pageof 12